| abstract |
Use of a compound of formula (I): 5-{5-[(2,4-dimethyl-1,3-thiazol-5-yl)methyl]-1,3,4-oxadiazol-2-yl}-1-ethyl- N -(tetrahydro-2 H -pyran-4-yl)-1 H -pyrazolo[3,4- b ]pyridin-4-amine (I) or a pharmaceutically acceptable salt thereof for the treatment of Huntington's disease. |